

**EP 0 357 067 B1**



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number: **0 357 067 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **01.02.95** (51) Int. Cl.<sup>6</sup>: **C12N 15/19, C12P 21/02,  
C12N 5/10, A61K 38/00**  
(21) Application number: **89116105.1**  
(22) Date of filing: **31.08.89**

(54) Recombinant natural killer cell activator.

- (30) Priority: **31.08.88 JP 217599/88**  
(43) Date of publication of application:  
**07.03.90 Bulletin 90/10**  
(45) Publication of the grant of the patent:  
**01.02.95 Bulletin 95/05**  
(84) Designated Contracting States:  
**AT BE CH DE ES FR GB GR IT LI LU NL SE**  
(56) References cited:  
**EP-A- 83 777**  
**EP-A- 181 524**  
  
**Journal of Experimental Medicine, vol. 168,  
no. 6, 01 December 1988, New York, pages  
2295-2308; Mc Grogan M. et al.: "Isolation of  
a cDNA clone encoding a precursor to hu-  
man eosinophil Major Basic Protein"**  
  
**Chemical Abstracts, vol. 103, no. 7, 19 Au-  
gust 1985, Columbus, Ohio, USA; SAYERS, T.  
et al: "In vivo Activation of Murine Natural  
Killer Cell Functions by Human Recombinant  
DNA Interleukin 2" page 450**  
  
(73) Proprietor: **Eisai Co., Ltd.**

6-10, Kolshikawa 4-chome  
Bunkyo-ku  
Tokyo (JP)  
  
(72) Inventor: **Yoshimatsu, Kentaro**  
**9-44, Ottominami 2-chome**  
**Tsuchiura-shi**  
**Ibaraki (JP)**  
Inventor: **Ohya, Yukio**  
**3137-37, Ushikumachi**  
**Ushiku-shi**  
**Ibaraki (JP)**  
Inventor: **Shikata, Yasushi**  
**15-1-306, Namiki 4-chome**  
**Tsukuba-shi**  
**Ibaraki (JP)**  
Inventor: **Tanaka, Isao**  
**5-16, Ninomiya 2-chome**  
**Tsukuba-shi**  
**Ibaraki (JP)**  
Inventor: **Hasegawa, Yoshikazu**  
**6-8, Nishinodai**  
**Yawaharamura**  
**Tsukuba-gun**  
**Ibaraki (JP)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Inventor: **Seto, Toshio**  
**3-160-2, Sakaecho**  
**Ushiku-shi**  
**Ibaraki (JP)**  
Inventor: **Osawa, Toshiaki**  
**9-13, Akatsukashinmachi 1-chome**  
**Itabashi-ku**  
**Tokyo (JP)**

(74) Representative: **Kolb, Helga, Dr. Dipl.-Chem. et al**  
**Hoffmann, Eitlie & Partner,**  
**Patentanwälte,**  
**Postfach 81 04 20**  
**D-81904 München (DE)**

**Description**

This invention relates to a novel polypeptide which enhances the activity of natural killer cells (NK cells) in lysing human tumor cells; to a genetic engineering technique relating to the production thereof; and a drug containing said peptide as an active ingredient. Accordingly, the present invention is useful in the field of drugs.

**[Prior Art]**

It has been known that there are natural killer cells (NK cells) which show a destructive effect on specific cancer cells. Thus lymphokines affecting the activity of these NK cells have attracted attention. For example, it is reported that interleukin-2 and interferon enhance the activity of NK cells [Herberman, R.B., et al., *Immunol. Rev.*, 44, 13 (1979); Vose, B.M., et al., *J. Immunol.*, 130, 768 (1983); Domzig, W., et al., *J. Immunol.*, 130, 1970 (1983)].

NK cells play various important roles as one of the non-specific host defense systems, for example, the first step of defense against cancer cells, suppression of the metastasis of cancer cells, resistance against viral infection and regulation of hematopoiesis in bone marrow [Kurnagai, K. and Ito, K., *Nippon Rinsho, Special Spring Issue*, 42, 859 (1984)].

The following facts indicate that NK cells play important roles in the host defense against cancer. Namely, a nude mouse lacking T cells but having a high NK activity does not always suffer from spontaneous or chemically induced carcinogenesis at a high frequency [Rygaard, J. et al., *Immunol. Rev.*, 28, 43 (1975); Stutman, D., et al., *Science*, 183, 534 (1974)]; and the metastasis of transplanted cancer cells is promoted in a beige mouse having T cells but a genetically low NK activity [Shimamura, K. and Tamaoki, K., *Jikken Igaku*, 2, 398 (1984); James, E., Talmadge, et al., *Nature*, 284, 622 (1980)] and a mouse having an artificially lowered NK activity [Shimamura, K. and Tamaoki, K., *Jikken Igaku*, 2, 398 (1984)].

Sistara et al. reported that an NK cell activity enhancing factor different from interleukin-2 is produced and liberated from mouse thymocytes [Sistara, K., Ichimura, O., Mitsuno, T. and Osawa, J., *Immunol.*, 134, 1039 (1985)].

Some of the present inventors presumed the presence of a lymphokine capable of activating NK cells, established several cell lines of lymphokine producing human T cell hybridomas and demonstrated the presence of some lymphokines such as a macrophage migration inhibitory factor (MIF) and a macrophage activating factor (MAF) [Kobayashi, Y., Asada, M., Higuchi, M. and Osawa, T., *J. Immunol.*, 128, 2714 (1982); Asada, M., Higuchi, M., Kobayashi, Y. and Osawa, T., *Cell. Immunol.*, 77, 150 (1983); Higuchi, M., Asada, M., Kobayashi, Y. and Osawa, T., *Cell. Immunol.*, 78, 257 (1983)].

In particular, they found that a human T cell hybridoma obtained from human T cells treated with keyhole limpet hemocyanin could produce a completely novel NK cell activating factor, which will be abbreviated to NKAF hereinbelow, different from any known lymphokine, as disclosed in Japanese Patent Laid-Open No. 97224/1986. In this invention, however, the obtained NKAF was a natural product per se and the amino acid sequence thereof as a peptide was not clearly specified.

In order to apply an NKAF as a drug on an industrial scale, it is necessary to clarify the amino acid sequence thereof as a peptide and to mass-produce it as a genetic recombination product obtained through a genetic engineering technique.

Thus the present inventors have attempted to isolate and identify the NKAF which enhances the activity of NK cells so as to obtain its gene.

Accordingly, it is a first object of the present invention to purify the natural NKAF disclosed in the Japanese Patent Laid-Open No. 97224/1986 and to specify the partial amino acid sequence thereof. It is a second object of the present invention to select a specific cDNA clone from a cDNA library prepared from the mRNA of the human T cell hybridoma based on the abovementioned sequence to thereby finally obtain a recombinant NKAF product.

As the first step for achieving the above-mentioned objects the present inventors purified the natural NKAF by immuno-affinity column chromatography and specified the partial amino acid sequence thereof.

Next, they selected a desired cDNA clone from a cDNA library prepared from the mRNA of the human T cell hybridoma (C-108) based on the amino acid sequence (KR-21) specified above. Subsequently the amino acid sequence of the NKAF was specified from the base sequence of the cDNA clone pNK8308 thus obtained. Further the recombinant NKAF was manifested and its activity was confirmed.

Based on these findings, they have conducted further examination, thus completing the present invention.

Now the present invention will be described in detail.

## ( Summary of the Invention )

The invention provides a recombinant natural killer cell activating factor having a peptide of the following amino acid sequence in its molecule. The invention provides a cDNA coding for a recombinant natural killer cell activating factor, a manifestation plasmid involving the cDNA, a host transformed with the plasmid, an antitumor agent containing the recombinant natural killer cell activating factor and a pharmaceutical composition which comprises a pharmacologically effective amount of the antitumor agent and a pharmacologically acceptable carrier.

10

```

LeuHisLeuArgSerGluThrSerThrPheGluThrProLeu
      10
GlyAlaLysThrLeuProGluAspGluGluThrProGluGln
      20
      30          40
GluMetGluGluGluThrProCysArgGluLeuGluGluGlu
      50
GluTrpGlySerGlySerGluAspAlaSerLysLysAspGly
      60          70
      20          80
AlaValGluSerIleSerValProAspMetValAspLysAsn
      90
LeuThrCysProGluGluGluAspThrValLysValValGly
      100
      25          110
IleProGlyCysGlnThrCysArgTyrLeuLeuValArgSer
      120
LeuGlnThrPheSerGlnAlaTrpPheThrCysArgArgCys
      130          140
      30          150
TyrArgGlyAsnLeuValSerIleHisAsnPheAsnIleAsn
      160
      35          170          180
TyrArgIleGlnCysSerValSerAlaLeuAsnGlnGlyGln
      190
      40          200          206
ValTrpIleGlyGlyArgIleThrGlySerGlyArgCysArg
      210
ArgPheGlnTrpValAspGlySerArgTrpAsnPheAlaTyr
      220
      45          230          240
TrpAlaAlaHisGlnProTrpSerArgGlyGlyHisCysVal
      250
      50          260
AlaLeuCysThrArgGlyGlyTyrTrpArgArgAlaHisCys
      270
      55          280          290
LeuArgArgLeuProPheIleCysSerTyr

```

45 The final target product of the present invention may be produced through genetic engineering techniques.

Therefore a cDNA coding for the recombinant NKAF of the present invention and a manifestation plasmid containing said cDNA as an alien gene and obtained by linking in such a manner as to enable the regulation and manifestation in a selected host, both of which are intermediates required in the production 50 of the final target product of the present invention, constitute the present invention together to thereby contribute to the solution of the same problem.

A preferred cDNA is the cDNA according to Claim 3, furthermore, a host transformed with said manifestation plasmid also constitute the present invention like the abovementioned cDNA and manifestation plasmid. As the host, Escherichia coli, yeasts and animal cells such as BHK cells and CHO cells may 55 be employed.

An example of an E. coli strain carrying the cDNA is one discriminated as XLI-Blue/pNK 8308 B which will be described in Example 1. The strain has been deposited with Fermentation Research Institute as FERM P-10161, now transferred to the international deposit, FERM BP-2468.

The recombinant NKAF of the present invention, i.e., the final target product has an antitumor activity, as will be shown in Examples hereinafter.

Similar to the natural NKAF which is available as an active ingredient of a drug composition and applied to medical uses, therefore, the recombinant NKAF of the present invention may be used as an active ingredient of a drug composition to thereby apply its activity to therapeutic purposes.

In this case, said drug composition may be usually formulated into an intravenous injection.

The injection may be prepared in a conventional manner employed in the art in the formulation of a trace amount of a physiologically active substance into an injection.

For example, the recombinant NKAF of the present invention may be formulated into an aqueous solution either alone or together with appropriate filler(s) or solubilizing agent(s), filtered under sterile conditions, packed lyophilized and combined with an aqueous solution for dissolution. Thus an injection which is to be dissolved at use may be prepared.

#### [Method]

15

Now the production and determination of the natural NKAF will be described.

##### 1. Production of purified natural NKAF:

20 In order to produce the recombinant NKAF, the purification of the natural NKAF and the analysis of its structure are conducted in the following manner.

Natural NKAF may be purified from a serum-free culture supernatant of a clone C-108 line of natural NKAF-producing human T cell hybridoma KC-8-1-10 (cf. Japanese Patent Laid-Open No. 97224/1986) through various methods including ion exchange chromatography, gel filtration chromatography, affinity chromatography and high performance liquid chromatography.

The determination of the N-terminal amino acid sequence of the purified NKAF thus obtained and the amino acid sequence of a purified NKAF fragment peptide obtained by enzymatically digesting the same with trypsin enable the cloning of the cDNA.

30 The effect of the NKAF in enhancing the NK activity may be determined by utilizing the activity of plastic nonadherent human peripheral blood lymphocytes (plastic nonadherent PBLs) in killing human cancer cell line K-562 cells (NK activity) as the guidance. Namely, a sample is subjected to double-serial dilution with an RPMI-1640 medium containing 10% of fetal calf serum (10% FCS-RPMI-1640). 50- $\mu$ l portions of the diluted samples were introduced into a 96-well microplate. Next  $1 \times 10^5$ /50  $\mu$ l of the plastic nonadherent PBLs were added thereto and incubated therein at 37°C for 16 hours. Then  $1 \times 10^4$ /100  $\mu$ l of a  $^{51}\text{Cr}$ -labeled K-562 cell suspension was added thereto and incubated therein at 37°C for additional four hours.

35 Separately, 100  $\mu$ l of the 10% FCS-RPMI-1640 medium was incubated for 16 hours and then 100  $\mu$ l of a  $^{51}\text{Cr}$ -labeled K-562 cell suspension was added thereto, followed by incubating for additional four hours as a control. The released  $^{51}\text{Cr}$  in 100  $\mu$ l of the incubation is determined.

40

$$\text{NK activity (\%)} = \frac{(b - a)/(c - a)}{100} \times 100$$

45 In the above equation, b represents liberated  $^{51}\text{Cr}$  (cpm) of the sample; a represents liberated  $^{51}\text{Cr}$  (cpm) of the control; and c represents total  $^{51}\text{Cr}$  (cpm) in 100  $\mu$ l of the  $^{51}\text{Cr}$ -labeled K-562 cell suspension ( $10^5/\text{ml}$ ). The determination is to be conducted triplicate and the mean value is calculated.

The NKAF activity corresponding to 50% of the maximum enhancing effect under these conditions may be defined as 1 U.

An example of the production of the natural NKAF is as follows.

50

##### (1) Purification of natural NKAF:

A human T cell hybridoma KC8-1-10 C-108 line was grown in a 10% FCS-RPMI-1640 medium in a 10-1 glass jar until the cell density reached  $1 \text{ to } 2 \times 10^6$  cells/ml.

55 After the completion of the incubation, the cells were collected by centrifugation and washed with RDF medium. The washed cells were suspended in the RDF medium in such a manner as to give a density of  $1 \times 10^6$  cells/ml. The obtained suspension was continuously incubated in a glass jar at 37°C for 14 to 20 days.

The supernatant was continuously replaced with a fresh one at a rate of 10 l/day and the target NKAF was purified from the NKAF-containing supernatant by the following method.

200 l of the serum-free culture supernatant was filtered through a glass fiber filter paper GF/F available from Whatman Inc. to remove cell debris. The filtrate was eluted through a column packed with separeads 5 SP-900 available from Mitsubishi Chemical Ltd., a gel volume of 2 l, at a flow rate of 25 l/hr to remove hydrophobic low molecular weight substances such as phenol red. The eluates were pooled and the electric conductivity thereof was adjusted to that of a 10 mM Tris-HCl buffer (pH 8) containing 0.2 M of NaCl. Then it was treated with a DEAE-Sepharose column (mfd. by Pharmacia; gel vol.: 2 l) equilibrated with the 10 mM 10 Tris-HCl buffer (pH 8) containing 0.2 M of NaCl at a flow rate of 12 l/hr. This column was washed with the same buffer and then eluted with a 10 mM Tris-HCl buffer (pH 8) containing 0.6 M of NaCl.

4 l of the eluted fraction showing the NKAF activity was concentrated approximately 1000-fold on an ultrafiltration membrane (YM-5, mfd. by Amicon). The concentrated fraction was then treated with a Sephadex G-75 gel filtration column [mfd. by Pharmacia; 50 (i.d.) x 900 mm] equilibrated with a 0.1 M aqueous solution of NH<sub>4</sub>HCO<sub>3</sub> at a flow rate of 100 ml/hr to thereby remove high molecular weight 15 substances such as nucleic acids. Active fractions were pooled and combined. The combined active fractions (approximately 900 ml) were concentrated approximately 20-fold on a YM-5 membrane and then lyophilized.

The lyophilized matter thus obtained was then dissolved in 5 ml of a mixture of 0.1 M CH<sub>3</sub>COONa buffer (pH 5) with 0.1 M Na<sub>2</sub>SO<sub>4</sub> buffer (pH 5) (1 : 1).

20 The solution thus obtained was adsorbed by a Phenyl-5PW-RP column for fractionation [mfd. by Tosoh, 21.5 Ø x 150 mm]. Then it was eluted by using eluent A [0.1 M CH<sub>3</sub>COONa buffer(pH 5)/0.1 M Na<sub>2</sub>SO<sub>4</sub> buffer (5.0) = 1/1] and eluent B [eluent A/CH<sub>3</sub>CN = 1/1].

The elution was conducted by linearly increasing the proportion of the eluent B from 0 to 100% within three hours to thereby elute the NKAF.

25 Thus the main fraction was eluted during the retention time of 100 to 110 minutes and some portion thereof was eluted during 110 to 140 minutes under the above conditions.

It was confirmed that these active fraction could react with monoclonal antibodies, which will be described hereinafter, by EIA.

Thus the main active fractions eluted during the retention time of 100 to 110 minutes were collected, 30 lyophilized and were obtained the partially purified natural NKAF.

#### Brief Description of the Drawings:

Fig. 1 is a chromatogram which shows the result of the purification of the natural NKAF by a 35 monoclonal antibody column.

Fig. 2 shows EIA with two monoclonal antibodies.

Fig. 3 is a chromatogram which shows the result of the purification of the NKAF by reverse phase HPLC.

Fig. 4 shows the result of SDS-PAGE.

40 Figs. 5 and 6 show each the amino acid sequence of a peptide chain.

Fig. 7 shows the result of the separation and isolation of the C-terminal peptide.

Fig. 8 is the restriction enzyme cleavage map of the cDNA clone.

Fig. 9 shows the base sequence of the cDNA of pNK 8308 and the amino acid sequence of NKAF deduced therefrom.

45 Fig. 10 shows the construction process of pNK 8602 by utilizing pcD vector.

#### (2) Preparation of monoclonal antibody for natural NKAF and its column:

The partially purified natural NKAF obtained by the above process (1), which was used as an 50 immunizing antigen, was mixed with Freund's complete adjuvant to thereby give an emulsion. 0.2 ml/animal of this emulsion was intraperitoneally administered to mice thrice to thereby immunize these animals.

Next, the partially purified natural NKAF was administered to mice through the tail veins and the spleen of each animal was taken out three days thereafter. The spleen cells thus obtained was fused with mouse myeloma cells X63-Ag 8.6.5.3 (Flow Lab.) by using 45% polyethylene glycol 3350 (mfd. by Sigma).

55 Subsequently the fused cells were grown in a conventional manner [Galfré, G. and Milstein, C. et al., Methods in Enzymology, 73, 3 (1981)].

Then two types of hybridoma cells 19-E-7 and 29-C-8 producing an antibody absorbing the NKAF activity were selected.

The obtained hybridoma cells were transplanted into the abdominal cavities of mice, to which 0.5 ml portions of pristane of Aldrich had been intraperitoneally administered one week or more before, and the ascites fluid pooled in the abdominal cavity of each animal was collected.

- Both of the two monoclonal antibodies (29-C-8 and 19-E-7) were IgG<sub>1</sub>.
- 5 The obtained monoclonal antibody was purified by using protein A-agarose of Repligen and reacted with cyanogen bromide-activated Sepharose 4B (mfd. by Pharmacia) to thereby give an immobilized monoclonal antibody gel.

2. Structural analysis of highly purified natural NKAF:

- 10 The partially purified natural NKAF (Sephadex G-75 fraction) obtained in the above 1-(1) was subjected to affinity chromatography with the use of the immobilized monoclonal antibody gel prepared in the above item (2) and the active fraction was collected (cf. Fig. 1).
- 15 The obtained product was a highly purified natural NKAF having a specific activity of approximately  $1 \times 10^5$  U/mg of protein.
- 16 The properties of this product were analyzed and thus the following results were obtained.

(1) Amino acid composition analysis:

- 20 The desalted natural NKAF was solidified by drying on the bottom of a small test tube for hydrolysis. Then this tube was placed in a glass vial and 500 µl of 6 N HCl was poured into the bottom of the vial. Next, the material was evacuated together with the vial, and hydrolyzed with hydrochloric acid at 110 °C for 24 hours. The NKAF hydrolysate thus obtained was analyzed with an amino acid analyzer 6300 of Beckman System.
- 25 Table 1 shows the results.

Table 1

Amino acid analysis		
	Found	Calculated
Asx	14.0	14
Thr	11.5	13
Ser	13.2	16
Glx	29.3	29
Pro	8.0	9
Gly	16.4	17
Ala	10.0	10
Cys	9.8	12
Val	11.1	12
Met	2.1	2
Ile	7.6	8
Leu	14.9	14
Tyr	4.7	6
Phe	6.6	7
His	4.2	5
Lys	5.5	5
Arg	21.2	19

## (2) Sugar composition analysis:

The neutral sugar content of the obtained natural NKAF determined by the orcinol-sulfuric acid method was approximately 120 µg/mg of protein. The content of uronic acid therein determined by the carbazole-sulfuric acid method was approximately 300 µg/mg of protein.

Next, the sugar composition of the natural NKAF was analyzed. Table 2 shows the results.

Thus it was confirmed that the obtained natural NKAF was a glycoprotein containing a large amount of O-glycoside type sugar chains (mucopolysaccharides and mucin type sugar chains).

10

Table 2

15  
20

Sugar composition	
Sugar	Content (µg/mg of protein)
N-Acetylglucosamine or N-acetylgalactosamine	68 µg
Mannose	14 µg
Galactose	55 µg
Sialic acid	54 µg

## (3) Determination of NKAF by EIA

25  
30  
35

A well was coated with one of the two monoclonal antibodies, 29-C-8, and washed. Then the NKAF was added thereto and allowed to react at room temperature for one hour. Next, another monoclonal antibody 19-E-7, which had been biotinized, was added thereto and the mixture was allowed to react at room temperature for one hour. After washing, avidin-peroxidase is further added thereto and the obtained mixture was allowed to react at room temperature for 30 minutes. After washing, a solution of o-phenylenediamine, i.e. the substrate, was added. Then color was developed at room temperature. 15 minutes thereafter, the reaction was ceased with 1 N HCl and the absorbance ( $OD_{492}$ ) was measured. Fig. 2 shows a calibration curve thus formed.

40

## (4) Removal of sugar chains:

Since the NKAF contained a number of sugars, the removal of sugar chains was examined for sequencing amino acids.

45

The analysis was conducted through SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and Western-immunoblotting. More precisely, the desalted and purified NKAF was treated with sialidase, O-glycanase, chondroitinase and heparitinase and it was examined by the SDS-PAGE whether sugar chains were incised thereby or not.

50

No change was observed before and after the treatment with heparitinase. The molecular weight of the main band of the NKAF was lowered by treating with sialidase or O-glycanase, though the smear did not disappear. When chondroitinase was used, the smear disappeared and a main band was observed at 35 KD. It was confirmed by the Western immunoblotting that this band reacted with the anti-NKAF monoclonal antibody and rabbit anti-NKAF antibody. The activity was sustained after the treatment with chondroitinase.

The desalted and purified NKAF was subjected to reductive carboxamidomethylation and dissolved in 100 mM Tris-HCl buffer (pH 8) containing 0.5 U of chondroitinase and 30 mM  $CH_3COONa$ . Then it was allowed to react at 37 °C for 60 minutes to thereby incise the chondroitin sulfate chain.

The reaction mixture was purified by reverse phase HPLC using a Vydac C4 column and 0.1% TFA (trifluoroacetic acid)/CH<sub>3</sub>CN System as a solvent while linearly altering the proportion of the CH<sub>3</sub>CN from 0 to 100% within 30 minutes at a flow rate of 1.5 ml/min (cf. Fig. 3).

55

When Fr.1 and Fr.2 on the chromatogram of Fig. 3 were subjected to the SDS-PAGE, Fr.1 showed a monoband at 35 KD while Fr.2 showed a smear band exceeding 35 KD (cf. Fig. 4). Fr.2 was dissolved in 50 mM Tris-HCl (pH 9) containing 6 M of guanidine hydrochloride and subjected to reverse phase HPLC. As a result, Fr.2 migrated toward Fr.1, suggesting that Fr.2 was an aggregation product of Fr.1.

(5) Analysis of N-terminal amino acid sequence:

The N-terminal amino acid sequence was analyzed by using Fr.1 of Fig. 3. Thus 28 N-terminal residues starting from leucine were specified as follows.

5

Leu-His-Leu-Arg-Ser-Glu-Thr-XXX-XXX-Phe-Glu-  
XXX-Pro-Leu-Gly-Ala-Lys-Thr-Leu-Pro-Glu-Asp-  
10 Glu-Glu-Thr-Pro-Glu-Gln.

No amino acid appeared on the 8th, 9th and 12th residues. Thus it was assumed as Ser or Thr to which an O-glycoside type sugar chain was bound.

15

(6) Peptide mapping of natural NKAF enzymatically digested with trypsin

Fr.1 of Fig. 3 was dissolved in 0.1 M ammonium hydrogen-carbonate (pH 8) containing 2 M of urea and trypsin was added thereto. The obtained mixture was allowed to react at 37°C for 16 hours. After the 20 completion of the reaction, the reaction mixture was purified by reverse phase HPLC using a Vydac C4 column and a solvent system of 0.1% TFA/CH<sub>3</sub>CN wherein the proportion of the CH<sub>3</sub>CN was linearly altered from 0 to 60% within 1 hour at a flow rate of 1.5 ml/min.

The amino acid composition and amino acid sequences of the 21 peptide fragments thus obtained were analyzed (cf. Table 3).

25

30

35

40

45

50

55

Table 3 amino acid sequence of peptides digested with  
trypsin

5

10

15

20

25

30

35

40

45

50

As the result of amino acid sequence analysis, the amino acid sequence of this peptide fragment was determined to be Arg-Leu-Pro-Phe-Ile-Cys-Ser-Tyr which agreed with the amino acid sequence of KR-17.

[Example]

- 5       Based on the amino acid sequence of the trypsin-hydrolyzed fragments of the purified specimen of the natural NKAF, as described above, the base sequence of the mRNA coding for the NKAF is estimated and a DNA oligomer corresponding thereto is synthesized. Next, a cDNA clone having a sequence coding for the NKAF is selected by screening through hybridization of a cDNA library originating from the mRNA of C-  
10 108 cells with the use of the above-mentioned oligomer as a probe.

To further illustrate the present invention, the following Examples will be given.

Example 1

15 (1) Isolation of mRNA:

$1.2 \times 10^9$  cells of KC-8-1-10 C-108 line, which had been stimulated with 4  $\mu$ l/ml of poke weed mitogen, PWM of GIBCO, in RPMI-1640 medium for eight hours, were collected and RNA was extracted therefrom by a method reported by Chirgwin et al. [Chirgwin, et al., Biochemistry, 18, 5294 (1979)].

20       3 parts by volume of the extract was then overlaid onto 1 part by volume of a 5.7 M CsCl-0.1 M EDTA solution and centrifuged at 26000 rpm at 25° for 36 hours with an ultracentrifuging machine (SRP 28 SA Roter; mfd. by Hitachi). Thus the aimed RNA was collected in the form of pellets.

25       The RNA thus obtained was dissolved in 10 mM Tris-HCl buffer (pH 7.4) and ethanol was added thereto. The obtained mixture was allowed to stand at -70°C for an hour. The RNA was precipitated by centrifugation and then dissolved in 10 mM Tris-HCl (pH 7.4). Further 0.5 M KCl was added thereto.

The obtained mixture was an oligo-(dT)cellulose column [20 mm  $\phi$  x 150 mm] equilibrated with the same buffer. After thorough washing with 0.5 M KCl and 10 mM Tris-HCl, the mRNA was eluted with a 10 mM aqueous solution of Tris-HCl.

30       500  $\mu$ g of the mRNA originating from the C-108 cells was overlaid on 15 ml of a solution containing a sucrose concentration gradient of 10% to 28% in 50 mM of Tris-HCL having pH of 7.4, 0.2 M of NaCl and 1 mM of EDTA. The resulting mixture was centrifuged at 26000 rpm and at 20°C for 16 hours with an ultracentrifuging machine (SRP 28 Roter; mfd. by Hitachi).

The obtained mixture was fractionated by 500- $\mu$ l portions and ethanol was added to each fraction to thereby precipitate the mRNA.

35       The mRNA in each fraction was dissolved in sterilized water in such a manner as to give an mRNA concentration of 1  $\mu$ g/ml.

Fractions containing mRNA of approximately 2 to 0.5 kb in size were collected and subjected to the subsequent reaction for synthesizing the cDNA.

40 (2) Formation of cDNA library:

The cDNA was synthesized according to a method reported by U. Gubler et al. [Gubler, U., et al., Gene, 25, 263 (1983)].

Namely, 1  $\mu$ g of the purified mRNA was treated with an Amersham cDNA synthesizing kit (code No. 45 RPN 12560 of Amersha.

The double-stranded cDNA was passed through a Sepharose CL-6B column and methylated by using a modifying enzyme EcoRI methylase. To the cDNA thus methylated was linked EcoRI linker (pGGAATTCC). Next, the material was incised with EcoRI to thereby give an EcoRI cohesive end. This cDNA was passed through a Sepharose CL-6B column to thereby remove the excessive EcoRI linker.

50       The cDNA thus purified was linked to  $\lambda$ gt 11, which had been incised with EcoRI and treated with phosphatase, at a molar ratio of 0.8 : 1 and packaged in phage particles. Thus a cDNA library comprising  $8 \times 10^6$  to  $1.4 \times 10^7$  clones was obtained.

This phage was plated onto ten plates of 15 cm in diameter and grown thereon. Thus 160 ml of a phage solution of a concentration of  $10^{11}$  pfu/ml was obtained.

55       Approximately 90% of the clones in the library had inserts. Eight clones, among ten selected at random, involved inserts of 300 bp to 2 kbp. The average size of these inserts was 1.2 kbp.

## (3) Preparation of DNA probe:

A probe corresponding to the first 12 residues ranging from tryptophan to tryptophan of the amino acid sequence of the trypsin-hydrolyzed fragment KR-21 (W-N-F-A-Y-X-A-A-H-Q-P-W-S-R) of the natural NKAF was prepared.

The unidentified residue X in the above sequence was tentatively assumed to be Ser. If a sugar chain would be bound to this residue, it should be Ser or Thr. However the analysis of the amino acid composition indicated that this sequence involved no Thr. Thus a probe was prepared based on the assumption that it was Ser.

On the other hand, the sequence of the mRNA coding for KR-21 was estimated by reference to a study on the frequency of the use of human genetic codons [Lathe, R., J. Mol. Biol., 183, 1 (1985)] and a DNA hybridization probe PKR-21 comprising 36 nucleotides complementary therewith was designed.

The sequence of the PKR-21 was as follows:

5'CCATGGCTGGTGGGGCAGCAGAGTAGGCAAAGTTCCA3'.

It was synthesized by using an automatic DNA synthesizer (mfd. by Applied Biosystems). This probe was 5'-end labelled with  $\gamma$ -<sup>32</sup>P-ATP and T4 polynucleotide kinase in a conventional manner.

## (4) identification of the cDNA clones containing the coding sequence of NKAF:

Approximately 160,000 recombinant phages were screened from the  $\lambda$ gt 11 cDNA library by the DNA hybridization method with the use of the <sup>32</sup>P-labeled PKR-21 probe.

Ten square plates (10x14cm) were plated with recombinant phages, with approximately 16,000 plaques formed on each plate. These plaques were transferred onto nitrocellulose membranes in a conventional manner [Mariatis, T. et al., "Molecular Cloning", 320 - 321 p, Cold Spring Harbor Laboratory (1982)) to thereby denature and immobilize the DNA.

These membranes were pre-hybridized in 6 x SSC [1 x SSC = 150 mM NaCl, 15 mM sodium citrate (pH 7)], 50 mM sodium phosphate (pH 7), 5 x Denhardt's (100 x Denhardt's = 2% bovine serum albumin, 2% polyvinylpyrrolidone, 2% Ficoll) and 100 micrograms per ml calf thymus DNA at 58 degree C for two hours.

Next, it was hybridized with the <sup>32</sup>P-labeled PKR-21 probe in 6 x SSC, 50 mM sodium phosphate (pH 7) and 5 x Denhardt's at 58°C for approximately 12 hours and washed with 6 x SSC-50 mM sodium phosphate at room temperature for 10 minutes twice, at 58°C for 30 minutes twice and at 65°C for 45 minutes once. Then clones capable of hybridizing with the pKR-21 were detected by autoradiography.

As a result, approximately 30 plaques were separately hybridized with the PKR-21. cDNAs were incised from four clones, among the abovementioned ones, with EcoRI and subcloned in a plasmid vector pBluescript ® Ks, M13<sup>+</sup> (mfd. by Stratagene, to thereby give pNK 8302, pNK 8303, pNK 8306 and pNK 8308 (deposited with Fermentation Research Institute as FERM P-10161, now transferred to the before mentioned international deposit).

The base sequences of these cDNA inserts were partially determined by the dideoxy chain termination method [Smith, A., Method in Enzymol., 65, 560; Sanger, F. et al., Proc. Acad. Sci., 74, 5463 (1977)]. As a result, it was found that all of them were cDNAs having various lengths involving sequences coding for the amino acid sequence of the NKAF. Fig. 8 shows the restriction enzyme cleavage maps of them.

Among these cDNAs, the longest one (pNK 8308) had a sequence of 850 bp except poly (A), in which an open reading frame (ORF) (666 bp) starting from an initiator codon and continuously coding 222 amino acid residues was observed (cf. Fig. 9). In this ORF, the peptide sequence of the KR-21 was identified as a fragment ranging from <sup>164</sup>W to <sup>177</sup>R. However the residue X unidentified in the KR-21 was not S but W.

Other trypsin-hydrolyzed peptide sequences were all identified on this ORF, which proved that this cDNA originated from the mRNA coding for the NKAF.

It was known that the N-terminal amino acid sequence of the purified NKAF specimen was <sup>1</sup>L-<sup>2</sup>H-<sup>3</sup>L-<sup>4</sup>R ..... , and it was further suggested that the polypeptide encoded by the cDNA pNK 8308 had a highly hydrophobic additional sequence consisting of 16 residues before the N-terminal sequence.

This might be a signal sequence for secreting the NKAF out of cells and incised at the secretion to thereby give mature NKAF starting from <sup>1</sup>L.

Example 2:

Manifestation of cDNA with COS7 cells:

- 5        The pcD vector has the origin of replication and the early promotor of SV 40 virus. See Okayama, H. and Berg., P., Mol. Cell. Biol., 3, 280 (1983). When the cDNA is integrated into the downstream of the promotor and introduced into a cell strain COS7, disclosed in Glutzman, Y., Cell., 231, 75(1981), producing the T antigen of the SV40, the recombinant plasmid is amplified and which induced intense transient manifestation of the cDNA is induced.
- 10      A Bgl II-Xho I fragment involving the whole coding region of NKAF cDNA was excised from the full-length clone pNK 8308 B, and linked to the pcDVI vector cleaved with Xho I and Hind III, together with a Hind III-Bam H I fragment of pLI to thereby form pNK 8602. See Fig. 10. Refer to Okayama, H. and Berg, P., Mol. Cell. Biol., 3, 280 (1980).
- 15      The cDNA was integrated into the downstream of the promotor in the correct orientation.
- 16      The plasmid DNA of the pNK 8602 was prepared and transfected to COS7 cells by the DEAE-dextran method [Yokohama, T. et al., Proc. Natl. Acad. Sci., 82, 68 (1985)]. The cells thus transfected produced NKAF in the culture supernatant approximately one day after transfection and continued the production for approximately five days. See Table 4.

20

25

30

35

40

45

50

55

5

10

15

20

25

30

35

40

45

50

Table 4

		Content (ug) of pNK 8602 DNA per 9.6 cm <sup>2</sup> well					
		0	0.1	0.4	1.5	6	24
1 - 2 Day	< 0.8 ng/ml	7.2 ± 0.3	13.2 ± 0.3	22.2 ± 0.7	24.7 ± 0.7	33.7 ± 1.3	
2 - 3 Day	< 0.8	9.5 ± 0.3	16.7 ± 0.2	22.7 ± 0.3	25.2 ± 0.2	30.0 ± 0.2	
3 - 4 Day	< 0.8	9.5 ± 0.3	16.0 ± 0.7	27.3 ± 0.3	27.7 ± 0.7	32.3 ± 0.8	
4 - 5 Day	< 0.8	1.7 ± 0.3	10.7 ± 0.7	18.2 ± 0.3	21.5 ± 1.3	25.5 ± 2.0	
5 - 6 Day	< 0.8	3.8 ± 0.3	10.5 ± 0.3	14.2 ± 0.7	15.5 ± 0.3	19.0 ± 0.2	

Note: Determined by EIA with the use of two monoclonal antibodies.

In the above determination, either DMEM medium containing 5% of FCS or serum-free HL-1 medium was available. See Table 5.

55

Table 5

NKAF in culture supernatant of COS7 cells transfected with pNK 8602 (incubated for 6 days)			
	Medium	Content of pNK 8602 DNA ( $\mu$ g)	rNKAF (ng/ml)
5	HL-1	6.25 $\mu$ g	48±2
		25 $\mu$ g	55±4
		100 $\mu$ g	54±2
10	5% FCS-DME	25 $\mu$ g	46±1

Note: Determined by EIA with the use of two monoclonal antibodies.

## 15 Example 3

Manifestation of NKAF in mammalian cell lines:

- 20 MTX(methotrexate)-resistant clones were obtained by co-transfected the pNK 8602 obtained in Example 1 and pSV2-dhfr [Subramani, S., Mulligan, R., Berg, P., Mol. Cell. Biol., 1, 854 (1981)] to BHK cells (ATCC, CRL 1632 tKts13, Dainippon Seiyaku) either by the elecroporation method (Bio-Rad, Gene Pulser® 0.4kV/0.4 cm, 500  $\mu$ F, 10-15 msec, twice) or the calcium phosphate method (Pharmacia, Cell Plect®) followed by selection with 250 nM of methotrexate.
- 25 These clones produced approximately 100 to 1,000 ng/ml of rNKAF in the medium (cf. Table 6). Furthermore, G418-resistant clones were obtained by co-transfected the pNK 8602 together with pSV2-dhfr and pSV2-neo [Southern, P.J. & Berg, P., J. Mol. Appl. Gent., 1, 327 (1982)] to CHO-KI cells by the calcium phosphate method [Kao, F.T. & Puck, T.T., Proc. Natl. Acad. Sci., 60, 1275 (1981)] followed by selection with 1 mg/ml of G-418. The obtained clones were further cultured in medium containing 5  $\mu$ M of MTX to thereby give clones capable of producing approximately 30 to 400 ng/ml of rNKAF (Cf. Table 7).

Table 6

NKAF in BHK/pNK 8602-pSV2-dhfr clone supernatant		
	Clone originating from BHK	rNKAF (ng/ml)
35	1 - 7	1,100
40	1 - 20	370
	1 - 21	1,016
	1 - 105	1,048
45	2 - 5	576
	2 - 42	798
	2 - 86	173

Note: Determined by EIA.

50

55

Table 7

NKAF in CHO/pNK 8602-pSV <sub>2</sub> -dhfr-pSV <sub>2</sub> -neo clone supernatant		
	Clone originating from CHO	rNKAF (ng/-mL)
5	3 - 10	37
	3 - 13	37
	3 - 2A	423
	3 - 10A	313
	3 - 13A	375
	Note: Determined by EIA.	

To illustrate the effects of the present invention, the following Test Examples will be given.

Test Example 1

20 1. Antitumor activity of natural NKAF:

Plastic nonadherent PBLs and the NKAF were added to 10% FCS-RPMI-1640 medium and incubated therein at 37°C for 2.5 hours and 16 hours. Then the cytotoxic activity against <sup>51</sup>Cr-labeled K-562, Molt-4 or Daudi cells was determined to thereby evaluate the NK-activity enhancing effect of the NKAF. Tables 8 and 25 9 show the results, wherein the control was assumed to be 100%.

30

35

40

45

50

55

5  
10  
15  
20  
25  
30  
35  
40  
45  
50

Table 8: NK-activity enhancing effect of natural NKAF

Exp. 1

Target cell	K-562
Control	100 %
0. 5U/ml	109 ± 4 %
1 U/ml	113 ± 1 %
Natural NKAF	116 ± 2 %
2 U/ml	118 ± 2 %
4 U/ml	122 ± 6 %
8 U/ml	122 ± 1 %
r-IL-2	122 ± 1 %

Exp. 2

Target cell	K-562
Control	100 %
0. 6U/ml	108 ± 3 %
1. 3U/ml	121 ± 1 %
Natural NKAF	2. 5U/ml
5 U/ml	126 ± 2 %
10 U/ml	129 ± 0 %
r-IL-2	178 ± 14 %

Note: The NK-activity of the control was assumed to be 100%.

Exp. 1: NK activity of control: 67%.

Exp. 2: NK activity of control: 40%.

Table 9 NK-activity of natural NKAF with various target cells

Target cell	K-562	Kolt 4		Daudi
		2.5 hr	16 hr	
Incubation time				
Control	100%	100%	100%	100%
Natural NKAF				
2U/ml	138 ± 5%	124 ± 1%	247 ± 15%	159 ± 5%
10U/ml	137 ± 7%	—	245 ± 7%	171 ± 8%
5U/ml	—	116 ± 6%	—	139 ± 8%
r-IL-2				
10U/ml	129 ± 13%	132 ± 7%	197 ± 17%	—
IFN-γ	500U/ml	109 ± 11%	144 ± 9%	170 ± 26%
				141 ± 11%
				251 ± 13%

As is apparent from Tables 8 and 9, the natural NKAF showed an effect of enhancing the NK activity comparable to those of recombinant interleukin-2 (r-IL-2; mfd. by Shionogi) and interferon-γ (IFN-γ; mfd. by Cellular Products Inc.).

Plastic nonadherent PBLs were mixed with Raji cells, which had been treated with mitomycin C, and incubated in a 10% FCS-RPMI-1640 medium at 37°C for six days. Then NKAF was added thereto and the

incubation was continued for additional one day.  $^{51}\text{Cr}$ -labeled Raji cells were further added thereto and the incubation was conducted for four hours. Then 100  $\mu\text{l}$  of the supernatant was collected and the  $^{51}\text{Cr}$  radioactivity thereof was measured to thereby examine the activity of killer T cells thus induced by the MLTR (mixed lymphocyte tumor cell reaction). Table 10 shows the results.

6 Thus it was found that the NKAF could enhance the activity of the killer T cells induced by the MLTR.

Table 10

		Killer T cell activity (%)
Control		42 $\pm$ 3
r-IL-2	10U/ml	59 $\pm$ 1
Natural NKAF	1.6U/ml	47 $\pm$ 7
	8U/ml	48 $\pm$ 1
	40U/ml	56 $\pm$ 3

20 Test Example 2

Antitumor activity of the recombinant NKAF

25 The NKAF activity of the BJK/pNK 8602-pSV<sub>2</sub>-dhfr clone supernatant was evaluated on the basis of the enhancement of the NK cell activity with the use of human cancer cell strain K-562 cells as target cells. Table 11 shows the results.

The enhancing effect was determined by assuming NK-activity of the control to be 100%. Table 12 shows the results.

30 Namely, the effects of the recombinant NKAF were almost comparable to those of the natural NKAF.

Table 11

NKAF activity of BHK/pNK 8602-pSV <sub>2</sub> -dhfr clone supernatant	
Clone originating from BHK cell	NKAF activity (U/ml)
1 - 7	160
1 - 21	80
2 - 42	40
1 - 105	120

45

50

55

Table 12 NK activity of  
BHK/pNK 8602-pSV<sub>2</sub>-dhfr clone  
supernatant (target cell: K-562)

BHK cell clone	1 - 7	1 - 21	
Dilution of clone supernatant (fold)	160	118 ± 1 %	113 ± 1 %
80	123 ± 2 %	113 ± 2 %	
40	124 ± 5 %	117 ± 1 %	
20	129 ± 6 %	133 ± 1 %	
Control		100 %	
r-IL-2	2.5U/ml	125 ± 4 %	

Note: NK activity of the control was

assumed to be 100%.

Example 4 : Example added to NKAF Patent Application (NKAF expression in Escherichia coli)

#### 1. Preparation of expression plasmid

The DNA encoding mature NKAF was prepared by removing the signal sequence from NKAF cDNA and was inserted between PL promoter of bacteriophage and rrnB terminator of E.coli. This expression unit was ligated to the vector pBR322 d-rop, which stably maintain a large copy number to construct an expression vector pNK8001.

##### 1) Construction of pBRD5001 (Fig.11)

pBRD5001 is obtained by replacing the vector portion of the lymphotoxin expression plasmid pTT5001 (Japanese Patent Application 272034/1987 by pBR322 d-rop (Japanese Patent Application 272034/1987 and expected to stably retain a large copy number of plasmid. This expression vector has trc promotor and rrnB terminator derived from pKK233-2 (mfd. by Pharmacia Fine Chemicals Co.).

##### 2) Construction off pPL9-5001 (Fig.12)

pPL9-5001 was constructed from pBRD5001, by replacing the promotor with PL promotor of bacteriophage . pPL- (mfd. by Pharmacia Fine Chemical Co.) was cleaved with EcoRI and HpaI to isolate an about 470 bp fragment containing PL promoter. This fragment was cleaved with Hae III to obtain an about 265 bp fragment and the fragment was ligated along with the DNA fragment of the following synthetic SD sequence :


5' TTAACAACTAAGGAGGA 3'  
 3' AATTGTTGATTCCCTCCTCTAG 5'

5

to EcoRI-BglII cleaved pUG131 plasmid [the plasmid obtained by replacing the polylinker of pUC13 (mfd. by Pharmacia Fine Chemicals Co.) for the polylinker of M13 tg131 (mfd. by Amercham Co.) (Japanese Patent Application 272034/1987)] to generate pPL9. pBRD5001 was cleaved with EcoRI and Bgl II to remove an about 300 bp fragment containing trc promoter and the fragment (PL promoter + SD) of about 280 bp produced by cleaving pPL9 with EcoRI was inserted to create pPL9-5001.

## 3) Construction of pBRD702 (Figs.13 and 14)

15 The nucleotide sequence CATATA coding His Leu of NKAF cDNA was converted into CATCTA by in vitro mutagenesis. The mutation introduced a new cleavage site for Afl II.



This variant NKAF cDNA was excised with Afl II to create the NKAF fragment without signal sequence. A synthetic DNA linker having a Bgl II-cohesive end and an initiation codon followed by a sequence coding 30 for Leu His was inserted upstream of the NKAF cDNA fragment and ligated to the vector fragment ( Bgl II - Sall ) of pEH7084 ( Japanese Patent Application 253302/1988 ), creating pENK702 (fig.13). In this plasmid, the cDNA coding for the mature NKAF is connected just downstream of trc promoter of pENK702 via the Bgl II site. A Bgl II - PvuI vector fragment of pBRD5001 and a Bgl II - PvuI NKAF cDNA fragment of pENK702 was then ligated thereto to create pBRD702 (Fig.14).

35

## 4) Construction of pNK8001 (Fig.15)

pPL9-5001, cleaved with Bgl II and then partially cleaved with Hind III, was separated by agarose-gel electrophoresis to isolate a vector fragment containing promoter and terminator. On the other hand, 40 pBRD702 was cleaved with Bgl II and Hind III to isolate the NKAF cDNA fragment, which was ligated to the above vector fragment to generate pNK8001. This constructed the expression plasmid having PL promoter, the mature NKAF cDNA and rrnB terminator ligated to pBR322 d-rop vector. The following expression experiments were conducted using pNK8001.

## 45 2. NKAF expression in E.coli

An E. coli strain, N4840 CI857, has a temperature sensitive mutation repressor and the induction of PL promoter is achieved by the high-temperature shift.

50 pNK8001 and its equivalent lymphotoxin expression plasmid pPL9-5001 were introduced into the strain N4840 via transformation to give an ampicillin-resistant transformants at 30 °C. The transformant of each plasmid was grown with shaking in LB medium at 32 °C until OD<sub>600</sub> of the medium reached about 0.2 (time 0). Then, the temperature was shifted to 42 °C and the culture was continued. After the shift, the culture medium was taken at each designated period and subjected to analysis.

The bacterial cells equivalent to 10 OD<sub>600</sub> (10 ml of the culutre medium in the case of OD-1) were 55 harvested by centrifugation and resuspended in 0.4 ml of the breaking buffer (0.2M Tris of pH 7.6, 0.2M NaCl, 0.01M Mg-Acetate, 0.01M 2-mercaptoethanol, 5% glycerol) Cells were broken by sonication and the homogenate was centrifuged to remove cell debris. Concentration of NKAF in the cell extract was analysed by EIA using rabbit anti-native NKAF antibody (Table 13). The production of NKAF was observed only in the

transformant possessing pNK8001 and its expression was induced by the temperature shift. The production reached maximum at 3 to 5 hours after the shift.

Table 13

Plasmid	NKAF expression in E. coli N 4840				
	0	1.5	3	5	7.5 h
pNK8001	3	5	26	33	19 ng/ml
pPL9-5001	2	-	-	-	3

The bacterial extract was subjected to EIA using rabbit anti-native NKAF antibody. One ml of the bacterial extract corresponds to 25 OD<sub>600</sub> of bacterial cells.

## Example 5

## (1) preparation of a secretive expression vector

A DNA encoding mature NKAF was prepared by removing the signal sequence from NKAF cDNA and was inserted downstream the GAL7 promotor alpha-prepro signal sequence. It was connected with YEp13 having a copying origin at 2 micrometers and the secretive expression vector pYNK1902 was obtained.

## (1-1) pTN1071

The pTN1071, shown in Fig. 16, has a structure such that GAL7 promoter disclosed in Japanese patent publication A 60-248181, synthetic OLIGO#01 and alpha-prepro signal sequence disclosed in Herskowitz et al., Cell 30, 933-943, 1982, are inserted pUC12. The vector has a starting codon ATG at the same position as GAL7 and for this reason it is expected to provide a large amount of transfer.

## (1-2) pYNK1902 (Fig. 17)

A HindIII-BgIII fragment of pTN1071 and a BgIII-XbaI fragment of pNK8308 were inserted into HindIII, XbaI site of the M13 mp19 disclosed in Messing et al. Gene 33, 103-119, 1985, to obtain pM1901. In vitro mutagenesis was conducted, using the phage for a casting master and synthetic OLIGO#02, to obtain pM1902 such that the DNA encoding a mature protein of NKAF just after the alpha-prepro signal sequence was added thereto and at the same time AfII site was inserted thereinto without changing the sequence of amino acids. The pM1902 was cut with BamHI into fragments. The fragment was inserted into YEp13 at the BamHI site to obtain pYNK1902. This plasmid has the GAL7 promoter and for the reason is expected to provide a high expression of transfer only when a culture does not comprise glucose, but galactose. Also it is expected to secrete NKAF into the culture because of the alpha-prepro signal sequence.

## (2) expression of NKAF with a yeast

In the Lithium method disclosed in Ito et al., J. Bacteriol. 153, 163-168, (1983), pYNK1902 was transformed to the yeasts EHA-1C and EHF-2C shown in Table 14. In the data, och2 is a variable species which cannot accept addition of mannose at the temperature sensitivity. See Japanese patent publication A 63-309180. The obtained products were cultivated, being stirred, at 25 degree C in a selected culture medium containing no leucin. Then glucose was replaced by galactose for the carbon source and the cultivation was continued by elevating the temperature to 34 degree C. Sampling was conducted from time to time. The sample was separated into the bacterial cells and the supernatant portion of the medium. The cells were mixed with PBS and glass beads, the resulting supernatant portion was broken with vortex and the supernatant of the medium was diluted to conduct EIA to natural NKAF with polyclonal antibody and monoclonal antibody. See Table 15. It was found that NKAF existed in the cells and then it was secreted and expressed in the supernatant of the medium.

Table 15

strain	Genotype
EHA-1 C	a leu2 pep4 gal2
EHF-2 C	a leu2 pep4 gal2 och2*

15

Table 16 EIA

(ng/ml/OD 600)

	hour	monoclonal antibody		polyclonal antibody	
		cell	broth	cell	broth
EHA-1 C	0	0	0	0	0
	4	5. 5	0. 6	9. 9	1. 1
	10	6. 5	1. 3	14. 5	1. 6
	24	6. 2	4. 3	15. 1	2. 7
EHF-2 C	0	0	0	0	0
	4	1. 7	0. 9	3. 1	1. 4
	10	3. 8	3. 6	7. 6	6. 8
	24	3. 1	6. 4	5. 8	13. 2

45

**Claims**

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

- 50 1. A recombinant natural killer cell activating factor, which has a peptide of the following amino acid sequence in its molecule:

55

5 Leu His Leu Arg Ser Glu Thr Ser Thr Phe Glu Thr Pro Leu  
 Gly Ala Lys Thr Leu Pro Glu Asp Glu Glu Thr Pro Glu Gin  
 10 30 40  
 Glu Met Glu Glu Thr Pro Cys Arg Glu Leu Glu Glu Glu Glu  
 50 60  
 Glu Trp Gly Ser Gly Ser Glu Asp Ala Ser Lys Lys Asp Gly  
 10 70  
 Ala Val Glu Ser Ile Ser Val Pro Asp Met Val Asp Lys Asn  
 80  
 Leu Thr Cys Pro Glu Glu Glu Asp Thr Val Cys Val Val Gly  
 90  
 15 Ile Pro Gly Cys Gin Thr Cys Arg Tyr Leu Leu Val Arg Ser  
 100 110  
 Leu Gin Thr Phe Ser Gin Ala Trp Phe Thr Cys Arg Arg Cys  
 120  
 20 Tyr Arg Gly Asn Leu Val Ser Ile His Asn Phe Asn Ile Asn  
 130 140  
 Tyr Arg Ile Gin Cys Ser Val Ser Ala Leu Asn Gin Gly Gin  
 150  
 Val Trp Ile Gly Gly Arg Ile Thr Gly Ser Gly Arg Cys Arg  
 160  
 25 Arg Phe Gin Trp Val Asp Gly Ser Arg Trp Asn Phe Ala Tyr  
 Trp Ala Ala His Gin Pro Trp Ser Arg Gly Gly His Cys Val  
 170 180  
 30 Ala Leu Cys Thr Arg Gly Gly Tyr Trp Arg Arg Ala His Cys  
 190  
 200 206  
 Leu Arg Arg Leu Pro Phe Ile Cys Ser Tyr

- 40 3. The cDNA as claimed in Claim 2, which has the following base sequence:

45

50

55

CTTCATCTAAGGTCTGAGACTTCCACCTTGAGACCCCTTG  
 GGTGCTAAGACGCTGCCTGAGGATGAGGAGACACCAGAGCAG  
 5 GAGATGGAGGAGACCCCTTGAGGGAGCTGGAGGAAGAGGAG  
 GAGTGGGGCTCTGGAAGTGAAGATGCCCTCAAGAAAGATGGG  
 10 GCTGTTGAGTCTATCTCAGTGCCAGATATGGTGGACAAAAAC  
 CTTACGTGTCTGAGGAAGAGGACACAGTAAAAGTGGTGGC  
 15 ATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGGTGAGAAGT  
 CTTCAGACGTTAGTCAGCTGGTTACTGCCGGAGGTGC  
 TACAGGGGCAACCTGGTTCCATCCACAACTTCAATATTAAT  
 20 TATCGAACCTCAGTGTCTGTCAGCGCGCTAACCAAGGGTCAA  
 GTCTGGATTGGAGGCAGGATCACAGGCTGGGTGCTGCAGA  
 25 CGCTTCAAGTGGGTTGACGGCAGCCGCTGGAACTTGCCTAC  
 TGGGCTGCTACCCAGCCCTGGTCCCCTGGTGGTCACTGCCTG  
 30 GCCCTGTGTACCCGAGGAGGCTACTGGCGTCGAGCCCCTGC  
 CTCAGAAGACTTCCTTCATCTGTTCTAC

- 35 4. A manifestation plasmid involving a cDNA as set forth in Claim 2 or 3 as an alien gene and obtained by linking in such a manner as to enable regulation and manifestation in a selected host.  
 5. A host transformed with a plasmid as set forth in Claim 4.  
 40 6. An antitumor agent comprising a recombinant natural killer cell activating factor according to Claim 1.  
 7. A pharmaceutical composition which comprises a pharmacologically effective amount of the antitumor agent as defined in Claim 6 and a pharmacologically acceptable carrier.

45 **Claims for the following Contracting States : ES, GR**

- 50 1. The use of a recombinant natural killer cell activating factor, which has a peptide of the following amino acid sequence in its molecule:

5 Leu His Leu Arg Ser Glu Thr Ser Thr Phe Glu Thr Pro Leu  
 Gly Ala Lys Thr Leu Pro Glu Asp Glu Glu Thr Pro Glu Gln  
 10 Glu Met Glu Glu Thr Pro Cys Arg Glu Leu Glu Glu Gly Glu  
 Glu Trp Gly Ser Gly Ser Glu Asp Ala Ser Lys Lys Asp Gly  
 15 Ala Val Glu Ser Ile Ser Val Pro Asp Met Val Asp Lys Asn  
 Leu Thr Cys Pro Glu Glu Glu Asp Thr Val Lys Val Val Gly  
 20 Ile Pro Gly Cys Gln Thr Cys Arg Tyr Leu Leu Val Arg Ser  
 Leu Gln Thr Phe Ser Gln Ala Trp Phe Thr Cys Arg Arg Cys  
 25 Tyr Arg Gly Asn Leu Val Ser Ile His Asn Phe Asn Ile Asn  
 Tyr Arg Ile Gln Cys Ser Val Ser Ala Leu Asn Gln Gly Gln  
 Val Trp Ile Gly Gly Arg Ile Thr Gly Ser Gly Arg Cys Arg  
 Arg Phe Gln Trp Val Asp Gly Ser Arg Trp Asn Phe Ala Tyr  
 30 Trp Ala Ala His Gln Pro Trp Ser Arg Gly Gly His Cys Val  
 Ala Leu Cys Thr Arg Gly Gly Tyr Trp Arg Arg Ala His Cys  
 Leu Arg Arg Leu Pro Phe Ile Cys Ser Tyr

as an antitumor agent comprising the recombinant natural killer cell activating factor

- 40 2. The use of Claim 1 for the preparation of a pharmaceutical composition which comprises a pharmacologically effective amount of the antitumor agent as defined in Claim 1 and a pharmacologically acceptable carrier.

45 3. The use of a cDNA coding for a recombinant natural killer cell activating factor as defined in Claim 1 for the preparation of this natural killer cell activating factor.

4. The use of Claim 3, characterized in that the cDNA has the following base sequence:

CTTCATCTAAGGTCTGAGACTTCCACCTTGAGACCCCTTG  
 GGTGCTAAGACGCTGCCTGAGGATGAGGAGACACCAGAGCAG  
 5 GAGATGGAGGAGACCCCTTGAGGGAGCTGGAGGAAGAGGAG  
 GAGTGGGGCTCTGGAAGTGAAGATGCCCTCAAGAAAGATGGG  
 10 GCTGTTGAGTCTATCTCAGTGCCAGATATGGTGGACAAAAAC  
 CTTACGTGTCCTGAGGAAGAGGACACAGTAAAAGTGGTGGC  
 15 ATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGGTGAGAAGT  
 CTTCAGACGTTAGTCAGCTGGTTACTGCCGGAGGTGC  
 TACAGGGGCAACCTGGTTCCATCCACAACTTCAATATTAAT  
 20 TATCGAACCTCAGTGTCTGTCAAGCGCGCTAACCAAGGGTCAA  
 GTCTGGATTGGAGGCAGGATCACAGGCTCGGGTCGCTGCAGA  
 25 CGCTTCAAGTGGTTGACGGCAGCCGCTGGAACCTTGCCTAC  
 TGGGCTGCTACCAGCCCTGGTCCCAGGGTGGTCACTGCCTG  
 30 GCCCTGTGTACCCGAGGAGGCTACTGGCGTCGAGCCCCTGC  
 CTCAGAAGACTTCCTTCATCTGTTCCCTAC

35

5. Process for the preparation of a manifestation plasmid involving a cDNA as set forth in Claim 3 or 4 as an alien gene and by linking in such a manner as to enable regulation and manifestation in a selected host.
- 40 6. The use of a plasmid as prepared in Claim 5 for forming a host transformed with this plasmid.
7. Process for the preparation of a pharmaceutical composition by mixing a pharmacologically effective amount of the antitumor agent as defined in Claim 1 and a pharmacologically acceptable carrier.

45

#### **Patentansprüche**

**Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

50

1. Rekombinante natürliche Killerzellen aktivierender Faktor, dadurch gekennzeichnet, daß er in seinem Molekül ein Peptid der folgenden Aminosäuresequenz besitzt:

55

5            Leu His Leu Arg Ser Glu Thr Ser Thr Phe Glu Thr Pro Leu  
 Gly Ala Cys Thr Leu Pro Glu Asp Glu Glu Thr Pro Glu Glu  
 10          Glu Met Glu Glu Thr Pro Cys Arg Glu Leu Glu Glu Glu Glu  
 Glu Thr Pro Gly Ser Gly Ser Glu Asp Ala Ser Lys Lys Asp Gly  
 15          Ala Val Glu Ser Ile Ser Val Pro Asp Met Val Asp Lys Asn  
 20          Leu Thr Cys Pro Glu Glu Glu Asp Thr Val Cys Val Val Glu  
 Ile Pro Gly Cys Gln Thr Cys Arg Tyr Leu Val Arg Ser  
 25          Leu Gln Thr Phe Ser Gln Ala Trp Phe Thr Cys Arg Arg Cys  
 Tyr Arg Gly Asn Leu Val Ser Ile His Asn Phe Asn Ile Asn  
 30          Tyr Arg Ile Gln Cys Ser Val Ser Ile Leu Asn Gln Gly Gln  
 Val Trp Ile Gly Gly Arg Ile Thr Gly Ser Gly Arg Cys Arg  
 Arg Phe Gln Trp Val Asp Gly Ser Arg Trp Asn Phe Ala Tyr  
 35          Trp Ala Ala His Gln Pro Trp Ser Arg Gly Gly His Cys Val  
 Ala Leu Cys Thr Arg Gly Gly Tyr Trp Arg Arg Ala His Cys  
 40          Leu Arg Arg Leu Pro Phe Ile Cys Ser Tyr  
 45

2. cDNA, die für einen rekombinanten natürlichen Killerzellen aktivierenden Faktor gemäß Anspruch 1 codiert.  
 40         3. cDNA nach Anspruch 2, dadurch gekennzeichnet, daß sie die folgende Basensequenz besitzt:  
 45

50

55

CTTCATCTAAGGTCTGAGACTTCCACCTTGAGACCCCTTG  
GGTGCTAAGACGCTGCCTGAGGATGAGGAGACACCAGAGCAG  
5 GAGATGGAGGAGACCCCTTGAGGGAGCTGGAGGAAGAGGAG  
GAGTGGGGCTCTGGAAGTGAAGATGCCCTCCAAGAAAGATGGG  
10 GCTGTTGAGTCTATCTCACTGCCAGATATGGACAAAAAC  
CTTACGCTGTCTGAGGAAGAGGACACAGTAAAAGTGGTGGGC  
15 ATCCCTGGGTGCCAGACCTGCCGCTACCTCTGGTGAGAAGT  
CTTCAGACGTTAGTCAACCTGGTTACTGCCGGAGGTGC  
TACAGGGGCAACCTGGTTCCATCCACAACCTCAATATTAAT  
20 TATCGAACCTCAGTGGTCTGTCAGCGCGCTAACCGAGGTCAA  
GTCTGGATTGGAGGCAGGGATCACAGGCTGGGTGCGCTGCAGA  
25 CGCTTCACTGGGTTGACGGCAGCCGCTGGAACTTTGCGTAC  
TGGGCTGCTACCCAGCCCTGGTCCCAGGGTCACTGCGTG  
30 GCCCTGTGTACCCGAGGAGGCTACTGGCGTCGAGCCCCACTGC  
CTCAGAACACTTCCTTCACTGTTCTAC  
35

4. Manifestationsplasmid, dadurch gekennzeichnet, daß es eine cDNA nach Anspruch 2 oder 3 als Fremdgen enthält, und erhalten wurde, indem die Verknüpfung auf eine solche Weise durchgeführt wurde, um eine Regulierung und Manifestation in einem ausgewählten Wirt zu ermöglichen.
- 40 5. Wirt, dadurch gekennzeichnet, daß er mit einem Plasmid nach Anspruch 4 transformiert ist.
6. Antitumoragens umfassend einen rekombinanten natürlichen Killerzellen aktivierenden Faktor nach Anspruch 1.
- 45 7. Pharmazeutische Zusammensetzung, dadurch gekennzeichnet, daß sie eine pharmakologisch wirksame Menge des Antitumormittels nach Anspruch 6 und einen pharmakologisch annehmbaren Träger umfaßt.

**Patentansprüche für folgende Vertragsstaaten : ES, GR**

- 50 1. Verwendung eines rekombinanten natürlichen Killerzellen aktivierenden Faktors, der in seinem Molekül ein Peptid mit der folgenden Aminosäuresequenz aufweist:

5 Leu His Leu Arg Ser Glu Thr Ser Thr Phe Glu Thr Pro Leu  
 Gly Ala Lys Thr Leu Pro Glu Asp Glu Glu Thr Pro Glu Cys  
 10 Glu Met Glu Glu Thr Pro Cys Arg Glu Leu Glu Glu Gly Glu  
 Glu Thr pGly Ser Gly Ser Glu Asp Ala Ser Lys Lys Asp Gly  
 15 Ala Val Glu Ser Ile Ser Val Pro Asp Met Val Asp Lys Asn  
 Leu Thr Cys Pro Glu Glu Glu Asp Thr Val Cys Val Val Gly  
 Ile Pro Gly Cys Gln Thr Cys Arg Tyr Leu Leu Val Arg Ser  
 20 100 Leu Gln Thr Phe Ser Gln Ala Trp Phe Thr Cys Arg Arg Cys  
 Tyr Arg Gly Asn Leu Val Ser Ile His Asn Phe Asn Ile Asn  
 Tyr Arg Ile Gln Cys Ser Val Ser Ala Leu Asn Gln Gly Gln  
 25 130 Val Trp Ile Gly Gly Arg Ile Thr Gly Ser Gly Arg Cys Arg  
 Arg Phe Gln Trp Val Asp Gly Ser Arg Trp Asn Phe Ala Tyr  
 Trp Ala Ala His Gln Pro Trp Ser Arg Gly Gly His Cys Val  
 Ala Leu Cys Thr Arg Gly Gly Tyr Trp Arg Arg Ala His Cys  
 30 180 150 120 100 180  
 Leu Arg Arg Leu Pro Phe Ile Cys Ser Tyr

als Antitumormittel, das den rekombinanten natürliche Killerzellen aktivierenden Faktor umfasst.

- 40 2. Verwendung nach Anspruch 1 zur Herstellung einer pharmazeutischen Zusammensetzung, die eine pharmakologisch wirksame Menge des in Anspruch 1 definierten Antitumormittels 1 und einen pharmakologisch annehmbaren Träger umfaßt.

45 3. Verwendung einer einen rekombinanten natürlichen Killerzellen aktivierenden Faktor nach Anspruch 1 codierenden cDNA zur Herstellung dieses natürlichen Killerzellen aktivierenden Faktors.

4. Verwendung nach Anspruch 3, dadurch gekennzeichnet, daß die cDNA die folgende Basensequenz besitzt:

CTTCATCTAAGGTCTGAGACTTCCACCTTGAGACCCCTTG  
 GGTGCTAAGACGCTGCCTGAGGATGAGGAGACACCAGAGCAG  
 5 GAGATGGAGGAGACCCCTTGAGGGAGCTGGAGGAAGAGGAG  
 GAGTGGGGCTCTGGAAGTGAAGATGCCCTCCAAGAAAGATGGG  
 10 GCTGTTGAGTCTATCTCAGTGCCAGATATGGTGGACAAAAAC  
 CTTACGTGTCTGAGGAAGAGGACACAGTAAAAGTGGTGGGC  
 15 ATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGGTGAAGT  
 CTTCAGACATTAGTCAGCTGGTTACCCACAACCAATTAAAT  
 TATCGAACCTGGTTCATCCACAACTCAATATTAAT  
 20 GTCTGGATTGGAGGCAGGATCACAGGCTCGGGTGCCTGCAGA  
 CGCTTCACTGGGTTGACGGCAGCCGCTGGAACTTTGCGTAC  
 25 TGGGCTGCTCACCAAGCCCTGGTCCCGCGGTGGTCACTGCCTG  
 30 GCCCTGTGTACCCGAGGAGGCTACTGGCGTGCAGCCCACGT  
 CTCAGAAGACTTCCTTCATCTGTTCTAC

35

5. Verfahren zur Herstellung eines Manifestationsplasmids, daß eine cDNA nach Anspruch 3 oder 4 als Fremdgen enthält, wobei die Verknüpfung auf eine Weise durchgeführt wird, die eine Regulierung und Manifestation in einem ausgewählten Wirt ermöglicht.
- 40 6. Verwendung eines nach Anspruch 5 hergestellten Plasmids zur Ausbildung eines mit diesem Plasmid transformierten Wirts.
- 45 7. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung durch Vermischen einer pharmakologisch wirksamen Menge des Antitumormittels nach Anspruch 1 mit einem pharmakologisch annehmbaren Träger.

**Revendications****Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

50

1. Activateur des cellules tueuses naturelles recombinant, possédant au sein de sa molécule un peptide dont la séquence d'acides aminés est la suivante:

55

10  
 Leu<sup>His</sup>LeuArgSerGluThrSerThrPheGluThrProLeu  
 GlyAlaLysThrLeuProGluAspGluGluThrProGluGln  
 20  
 GluMetGluGluGluThrProCysArgGluLeuGluGluGlu  
 30  
 Glu<sup>Trp</sup>GlySerGlySerGluAspAlaSerLysLysAspGly  
 40  
 AlaValGluSerIleSerValP<sup>ro</sup>AspMetValAspLysAsn  
 50  
 LeuThrCysProGluGluGluAspThrValLysValValGly  
 60  
 Ile<sup>Pro</sup>GlyCysGlnThrCysArgTyrLeuLeuValArgSer  
 70  
 100 LeuGlnThrPheSerGinAlaTrpPheThrCysArgArgCys  
 80  
 TyrArgGlyAsnLeuValSerIle<sup>His</sup>AsnPheAsnIleAsn  
 90  
 TyrArgIleGlnCysSerValSerAlaLeuAsnGinGlyGin  
 100  
 ValTrpIleGlyGlyArgIleThrGlySerGlyArgCysArg  
 110  
 120 ArgPheGlnTrpValAspGlySerArgTrpAsnPheAlaTyr  
 130  
 140  
 150  
 160  
 170  
 180  
 190  
 200  
 210  
 220  
 230  
 240  
 250  
 260  
 270  
 280  
 290  
 300  
 310  
 320  
 330  
 340  
 350

- 40 2. ADNc codant pour un activateur des cellules tueuses naturelles recombinant selon la revendication 1.

3. ADNc selon la revendication 2, qui possède la séquence de bases suivante:

45

50

55

CTTCATCTAAGGTCTGAGACTTCACCTTGAGACCCCTTG  
 GGTGCTAAGACCTGCCTGAGGATGAGGAGACACCAGAGCAG  
 5 GAGATGGAGGAGACCCCTTGAGGGAGCTGGAGGAAGAGGAG  
 GAGTGGGGCTCTGGAAGTGAAGATGCGCTCCAGAAAAGATGGG  
 10 GCTGTTGAGTCTATCTCAGTGCCAGATATGGTGGACAAAAAC  
 CTTACGTGTCTGAGGAAGAGGACACAGTAAAAGTGGTGGGC  
 15 ATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGGTGAGAAGT  
 CTTCAGACGTTAGTCAAGCTTGGTTACTTGCCGGAGGTGC  
 TACAGGGGCAACCTGGTTCCATCCACAACTTCAATATTAA  
 20 TATCGAACCTCAGTGTCTGTCAGCGCGCTAACCAAGGGTCAA  
 GTCTGGATTGGAGGCAGGGATCACAGGCTCGGGTCGCTGCAGA  
 25 CGCTTCACTGGTTGACGGCAGCCGCTGGAACCTTGCCTAC  
 TGGGCTGCTACCAGCCCTGGTCCCAGGGTGGTCACTGCCTG  
 30 GCCCTGTGTACCCGAGGAGGCTACTGGCGTCAGCCCCACTGC  
 CTCAGAAGACTTCCTTCATCTGTTCTAC

35

4. Plasmide d'expression comprenant un ADNc comme défini à la revendication 2 ou 3 en tant que gène étranger obtenu par ligature de manière à permettre une régulation et une expression dans un hôte choisi.
- 40 5. Hôte transformé avec un plasmide tel que décrit à la revendication 4.
6. Agent antitumoral comprenant un activateur des cellules tueuses naturelles recombinant selon la revendication 1.
- 45 7. Composition pharmaceutique comprenant une quantité efficace sur le plan pharmacologique d'un agent antitumoral tel que défini à la revendication 6 et un support acceptable sur le plan pharmacologique.

**Revendications pour les Etats contractants suivants : ES, GR**

50

1. Utilisation d'un activateur des cellules tueuses naturelles recombinant, possédant au sein de sa molécule un peptide dont la séquence d'acides aminés est la suivante:

55

5           LeuHisLeuArgSerGluThrSerThrPheGluThrProLeu  
 10          <sup>10</sup>  
 GlyAlaLysThrLeuProGluAspGluGluThrProGluGin  
 15          <sup>20</sup>  
 20          <sup>30</sup>  
 GluMetGluGluThrProCysArgGluLeuGluGlyGluGlu  
 25          <sup>40</sup>  
 30          <sup>50</sup>  
 GluTrpGlySerGlySerGluAspAlaSerLysLysAspGly  
 35          <sup>60</sup>  
 AlaValGluSerIleSerValProAspMetValAspLysAsn  
 40          <sup>70</sup>  
 45          <sup>80</sup>  
 LeuThrCysProGluGluGluAspThrValLysValValGly  
 50          <sup>90</sup>  
 IleProGlyCysGlnThrCysArgTyrLeuLeuValArgSer  
 55          <sup>100</sup>  
 60          <sup>110</sup>  
 LeuGinThrPheSerGlnAlaTrpPheThrCysArgArgCys  
 65          <sup>120</sup>  
 70          <sup>130</sup>  
 TyrArgGlyAsnLeuValSerIleHisAsnPheAsnIleAsn  
 75          <sup>140</sup>  
 TyrArgIleGlnCysSerValSerAlaLeuAsnGlnGlyGln  
 80          <sup>150</sup>  
 ValTrpIleGlyGlyArgIleThrGlySerGlyArgCysArg  
 85          <sup>160</sup>  
 ArgPheGlnTrpValAspGlySerArgTrpAsnPheAlaTyr  
 90          <sup>170</sup>  
 95          <sup>180</sup>  
 TrpAlaAlaHisGlnProTrpSerArgGlyGlyHisCysVal  
 100         <sup>190</sup>  
 105         <sup>200</sup>  
 AlaLeuCysThrArgGlyGlyTyrTrpArgArgAlaHisCys  
 110         <sup>210</sup>  
 115         <sup>220</sup>  
 LeuArgArgLeuProPheIleCysSerTyr  
 120         <sup>230</sup>  
 125         <sup>240</sup>  
 130         <sup>250</sup>  
 135         <sup>260</sup>  
 140         <sup>270</sup>  
 145         <sup>280</sup>  
 150         <sup>290</sup>  
 155         <sup>300</sup>  
 160         <sup>310</sup>  
 165         <sup>320</sup>  
 170         <sup>330</sup>  
 175         <sup>340</sup>  
 180         <sup>350</sup>  
 185         <sup>360</sup>  
 190         <sup>370</sup>  
 195         <sup>380</sup>  
 200         <sup>390</sup>  
 205         <sup>400</sup>  
 210         <sup>410</sup>  
 215         <sup>420</sup>  
 220         <sup>430</sup>  
 225         <sup>440</sup>  
 230         <sup>450</sup>  
 235         <sup>460</sup>  
 240         <sup>470</sup>  
 245         <sup>480</sup>  
 250         <sup>490</sup>  
 255         <sup>500</sup>  
 260         <sup>510</sup>  
 265         <sup>520</sup>  
 270         <sup>530</sup>  
 275         <sup>540</sup>  
 280         <sup>550</sup>  
 285         <sup>560</sup>  
 290         <sup>570</sup>  
 295         <sup>580</sup>  
 300         <sup>590</sup>  
 305         <sup>600</sup>  
 310         <sup>610</sup>  
 315         <sup>620</sup>  
 320         <sup>630</sup>  
 325         <sup>640</sup>  
 330         <sup>650</sup>  
 335         <sup>660</sup>  
 340         <sup>670</sup>  
 345         <sup>680</sup>  
 350         <sup>690</sup>  
 355         <sup>700</sup>  
 360         <sup>710</sup>  
 365         <sup>720</sup>  
 370         <sup>730</sup>  
 375         <sup>740</sup>  
 380         <sup>750</sup>  
 385         <sup>760</sup>  
 390         <sup>770</sup>  
 395         <sup>780</sup>  
 400         <sup>790</sup>  
 405         <sup>800</sup>  
 410         <sup>810</sup>  
 415         <sup>820</sup>  
 420         <sup>830</sup>  
 425         <sup>840</sup>  
 430         <sup>850</sup>  
 435         <sup>860</sup>  
 440         <sup>870</sup>  
 445         <sup>880</sup>  
 450         <sup>890</sup>  
 455         <sup>900</sup>  
 460         <sup>910</sup>  
 465         <sup>920</sup>  
 470         <sup>930</sup>  
 475         <sup>940</sup>  
 480         <sup>950</sup>  
 485         <sup>960</sup>  
 490         <sup>970</sup>  
 495         <sup>980</sup>  
 500         <sup>990</sup>  
 505         <sup>1000</sup>

en tant qu'agent antitumoral comprenant l'activateur des cellules tueuses naturelles recombinant.

- 40   2. Utilisation de la revendication 1 dans la préparation d'une composition pharmaceutique comprenant une quantité efficace sur le plan pharmacologique de l'agent antitumoral défini à la revendication 1 et un support acceptable d'un point de vue pharmacologique.
- 45   3. Utilisation d'un ADNc codant pour un activateur des cellules tueuses naturelles recombinant tel que défini à la revendication 1 pour la préparation de cet activateur des cellules tueuses naturelles.
- 50   4. Utilisation de la revendication 3, caractérisée en ce que l'ADNc possède la séquence de bases suivante:

55

55

CTTCATCTAAGGTCTGAGACTTCCACCTTGAGACCCCTTG  
 GGTGCTAAGACGCTGCCTGAGGATGAGGAGACACCAGAGCAG  
 5 GAGATGGAGGAGACCCCTTGAGGGAGCTGGAGGAAGAGGAG  
 GAGTGGGGCTCTGGAAGTGAAGATGCCCTCAAGAAAGATGGG  
 10 GCTGTTGAGTCTATCTCAGTGCCAGATATGGTGGACAAAAAC  
 CTTACGTGTCTGAGGAAGAGGGACACAGTAAAAGTGGTGGC  
 15 ATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGGTGAGAAGT  
 CTTCAGACGTTAGTCAAGCTTGGTTACTTGCCGGAGGTGC  
 20 TACAGGGCAACCTGGTTCCATCCACAACCTCAATATTAAAT  
 TATCGAACCTCAGTGGTCTGTCAGCGCGCTAACCAAGGGTCAA  
 GTCTGGATGGAGGCAGGGATCACAGGCTCEGGTCGCTGCAGA  
 25 CGCTTCACTGGGTTGACGGCAGCCGCTGGAACTTTCGTAC  
 TGGECTGCTACCCAGCCCTGGTCCCGGGTGGTCACTGCGTG  
 30 GCCCTGTGTACCCGAGGAGGCTACTGGCGTCGAGCCCCTGC  
 CTCAGAAGACTTCCCTCATCTGTTCTAC

- 35
5. Procédé de préparation d'un plasmide d'expression comprenant un ADNc comme défini à la revendication 3 ou 4 en tant que gène étranger obtenu par ligature de manière à permettre une régulation et une expression dans un hôte choisi.
  - 40 6. Utilisation d'un plasmide préparé selon la revendication 5 pour la formation d'un hôte transformé à l'aide de ce plasmide.
  - 45 7. Procédé de préparation d'une composition pharmaceutique par mélange d'une quantité efficace sur le plan pharmacologique d'un agent antitumoral tel que défini à la revendication 1 et d'un support acceptable sur le plan pharmacologique.

50

55

Fig. 1

29-C-8 purification with monoclonal antibody column




Fig. 2





FIG.3



Vydac C4.  
0.1%TFA/acetonitrile  
0-100% acetonitrile /30 min,  
A280(0.32AUFS), 1.5ml/min

FIG.4





FIG.5

EL A INJECT  
03/15/88 II 23 44



Vydac C4 0.1% TFA/acetonitrile  
0-60% acetonitrile /60min. A280(0.32AUFS)

Fig. 6

Leu His Leu Arg Ser Glu Thr Ser Thr Phe Glu Thr Pro Leu Gly Ala Lys Thr Leu Pro  
 KR-5 KR-9 KR-15, 18 KR-13 KR-8 KR-10 KR-19, 20 KR-16 KR-14 KR-1 KR-12 KR-11 KR-21 KR-6 KR-7 KR-2 KR-3 KR-17 KR-18 KR-19 KR-20 KR-21 KR-22 KR-23 KR-24 KR-25 KR-26 KR-27 KR-28 KR-29 KR-30 KR-31 KR-32 KR-33 KR-34 KR-35 KR-36 KR-37 KR-38 KR-39 KR-40

Fig. 7

KR-17 Arg-Leu-Pro-Phe-Ile-Cys-Ser-Tyr




Fig. 8




Fig. 9

10            20            30            40            50  
 AGGAAGCAAAGAAGGACCTGGGCTTGGGAAAGATCTAAAGACCCAGGAAGGTCTCTGGG  
 70            80            90            100          110  
 TGGGATAAAGCCAAGATGAAACTCCCCTTACTTCTGGCTCTTCTATTGGGCCAGTTCT  
 MetLysLeuProLeuLeuLeuAlaLeuLeuPheGlyAlaValSer  
 130          140          150          160          170  
 GCTCTTCATCTAAGGTCTGAGACTTCCACCTTGAGACCCCTTGGGTGCTAACAGCCTG  
 AlaLeuHisLeuArgSerGluThrSerThrPheGluThrProLeuGlyAlaLysThrLeu  
 190          200          210          220          230  
 CCTGAGGATGAGGAGACACCAGAGCAGGAGATGGAGGAGACCCCTTGCAGGGAGCTGGAG  
 ProGluAspGluGluThrProGluGlnGluMetGluGluThrProCysArgGluLeuGlu  
 250          260          270          280          290  
 GAAGAGGAGGAGTGGGGCTCTGGAAAGTGAAGATGCCTCCAAGAAAGATGGGGCTTTGAG  
 GluGluGluGluTrpGlySerGlySerGluAspAlaSerLysLysAspGlyAlaValGlu  
 310          320          330          340          350  
 TCTATCTCAGTGCCAGATATGGTGGACAAAAACCTTACGTGTCCTGAGGAAGAGGACACA  
 SerIleSerValProAspMetValAspLysAsnLeuThrCysProGluGluGluAspThr  
 370          380          390          400          410  
 GTAAAAGTGGTGGGCATCCCTGGGTGCCAGACCTGCCCTACCTCCTGGTGAGAAGTCTT  
 ValLysValValGlyIleProGlyCysGlnThrCysArgTyrLeuLeuValArgSerLeu  
 430          440          450          460          470  
 CAGACGTTAGTCAAGCTGGTTACTTGCCGGAGGTGCTACAGGGCAACCTGGTTTCC  
 GlnThrPheSerGlnAlaTrpPheThrCysArgArgCysTyrArgGlyAsnLeuValSer  
 490          500          510          520          530  
 ATCCACAACCTCAATATTAATTATCGAATCCAGTGTCTGTCAGCCGGCTCAACCAGGGT  
 IleHisAsnPheAsnIleAsnTyrArgIleGlnCysSerValSerAlaLeuAsnGlnGly  
 550          560          570          580          590  
 CAAGTCTGGATTGGAGGCAGGATCACAGGCTCGGTCGCTGCAGACGCTTCAGTGGTT  
 GlnValTrpIleGlyGlyArgIleThrGlySerGlyArgCysArgArgPheGlnTrpVal  
 610          620          630          640          650  
 GACGGCAGCCGCTGGAACTTTGGCTACTGGGCTGCTCACCGCCCTGGTCCCCGGTGGT  
 AspGlySerArgTrpAsnPheAlaTyrTrpAlaAlaHisGlnProTrpSerArgGlyGly  
 670          680          690          700          710  
 CACTGCGTGGCCCTGTGTACCCGAGGAGGCTACTGGCGTCGAGCCCCTGCCTCAGAAGA  
 HisCysValAlaLeuCysThrArgGlyGlyTyrTrpArgArgAlaHisCysLeuArgArg  
 730          740          750          760          770  
 CTTCCCTTCATCTGTTCTACTGAGCTGGTCCCAGCCAGCAGTTCAAGAGCTCCCTCTCC  
 LeuProPheIleCysSerTyr\*\*\*  
 790          800          810          820          830  
 TGGGCAGCTGCCCTCCCCCTCTGCTTGGCATCCCTCCACCTCCCTGCCAATAAAAT  
 850          860  
 CGCTTTACTGAAAAAAAAAAAAAA

Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 1 5





FIG. 16A



**FIG. B**

FIG.17

